FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.
What happened
FDA inspected the Durham, NC facility from November 28, 2023, to December 6, 2023, and documented significant current good manufacturing practice (CGMP) violations for two investigational CAR T cell products. FDA cited a box of food covered in scuttle fly pupae left in a mechanical room, scuttle fly larvae in ten monitoring samples and a live scuttle fly in a cleanroom, plus missing environmental monitoring and cleaning validation. CARsgen later paused manufacturing on December 12, 2023, and told clinics not to administer previously released products.
What FDA found
The firm found a box of food from June 16, 2023 covered in scuttle fly pupae in a mechanical room and did not remove it until July 31, 2023; later, scuttle fly larvae were found in ten environmental and personnel monitoring samples and a live scuttle fly was seen on a tube rack in a cleanroom.
21 CFR 211.56(a)The firm did not monitor non-viable particulates or viable microbes in air during open manufacturing in the aseptic processing area used for its products.
21 CFR 211.42(c)(10)(iv); 21 CFR 211.113(b)The firm had not validated the cleaning process for equipment used to make its sterile products and did not provide results from a disinfectant efficacy study.
21 CFR 211.42(c)(10)(v)The firm had no written procedure for 100% visual inspection of the final drug product to ensure it was essentially free from visible particulates.
21 CFR 211.100(a)Personnel microbial monitoring action-limit excursions occurred, proposed corrective and preventive actions were not implemented, more excursions occurred, and products were released afterward.
21 CFR 211.192
What FDA wants
FDA asks CARsgen to respond in writing within 15 working days with specific steps and documentation to correct the violations and prevent recurrence, or explain the delay and completion timeframe.
Who should pay attention
- clinical trial sponsors and sites using CARsgen products
- contract manufacturers and labs making sterile cell therapies
- quality teams managing aseptic environmental monitoring and cleaning validation
This is a summary. Read the original letter on fda.gov.